Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 11/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 11/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1415984 | 0.98 | ALDH1A1 (0.56) | ALDH1A1CHRNB2CHRNB4CHRNA4LMNA | |
| SCHEMBL7558675 | 0.98 | ALDH1A1 (0.56) | ALDH1A1CHRNB2CHRNB4CHRNA4LMNA | |
| SCHEMBL2537508 | 0.98 | ALDH1A1 (0.56) | ALDH1A1CHRNB2CHRNB4CHRNA4LMNA | |
| SCHEMBL7555488 | 0.98 | ALDH1A1 (0.56) | ALDH1A1CHRNB2CHRNB4CHRNA4LMNA | |
| SCHEMBL7555162 | 0.98 | ALDH1A1 (0.56) | ALDH1A1CHRNB2CHRNB4CHRNA4LMNA | |
| SCHEMBL2540699 | 0.98 | ALDH1A1 (0.56) | ALDH1A1CHRNB2CHRNB4CHRNA4LMNA | |
| SCHEMBL497804 | 0.92 | — | — | |
| SCHEMBL131476 | 0.87 | ALDH1A1 (0.74) | ALDH1A1CHRNB2CHRNB4CHRNA4LMNA | |
| SCHEMBL3189950 | 0.84 | ALDH1A1 (0.70) | ALDH1A1CHRNB2CHRNB4CHRNA4LMNA | |
| SCHEMBL422710 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6979690-B2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC. (US) | 2005-12-27 | — | — | US | claimed |
| US-20030207875-A1 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2003-11-06 | — | — | US | claimed |
| WO-2003057688-A2 | OXO OR OXY-PYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER JAPAN INC. (JP) | 2003-07-17 | — | — | WO | claimed |
| EP-1325921-A2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | Pfizer Inc. (US) | 2003-07-09 | — | — | EP | claimed |
| US-5843951-A | Analgesic composition of pyrazolo(1,5-A) pyrimidines | OTSUKA PHARMACEUTICAL FACTORY INC. (JP) | 1998-12-01 | — | — | US | claimed |
| EP-0795555-A1 | ANALGESICS | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1997-09-17 | — | — | EP | claimed |
| EP-2751084-B1 | PYRIMIDINE CARBOXAMIDE DERIVATIVES | EUDIS BIOTECH LLC (CN) | 2016-09-21 | — | — | EP | disclosed |
| CN-103917526-B | Pyrimidine carboxamide derivatives | 南京优迪生物医药有限公司 | 2016-08-24 | — | — | CN | disclosed |
| US-9249107-B2 | Pyrimidine carboxamide derivatives | MAEHR HUBERT (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150087665-A1 | Pyrimidine carboxamide derivatives | Maehr, Hubert (US) | 2015-03-26 | — | — | US | disclosed |
| EP-2834223-A2 | (1,2,3-TRIAZOLYL) SULFONYL DERIVATIVES | Apac Pharmaceutical LLC. (US) | 2015-02-11 | — | — | EP | disclosed |
| US-8853248-B2 | (1,2,3-triazolyl)sulfonyl derivatives | MAEHR HUBERT (US) | 2014-10-07 | — | — | US | disclosed |
| CN-103917526-A | Pyrimidine carboxamide derivatives | APAC PHARMACEUTICAL LLC | 2014-07-09 | — | — | CN | disclosed |
| US-5371098-A | Use of oxazole compounds to treat osteoporosis | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-12-06 | — | — | US | disclosed |
| EP-0376197-B1 | Sulfur-containing heterocyclic compounds | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-10-12 | — | — | EP | disclosed |
| US-5239080-A | Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-08-24 | — | — | US | disclosed |
| US-5158943-A | Osteoporosis | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-27 | — | — | US | disclosed |
| EP-0460488-A1 | Sulfur-containing heterocyclic compounds | Takeda Chemical Industries, Ltd. (JP) | 1991-12-11 | — | — | EP | disclosed |
| US-5071841-A | For prevention of bone reabsorption | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-12-10 | — | — | US | disclosed |
| EP-0440183-A1 | Oxazole compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207875-A1 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | HRH4, HRH2, HTR4 | ALDH1A1 2035/4885CHRNB2 429/4885CHRNB4 194/4885 |
| US-20150087665-A1 | Pyrimidine carboxamide derivatives | NOD1, IL1B, IRAK1 | ALDH1A1 98/4885CHRNB2 4764/4885CHRNB4 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.